Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 13/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 5/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.44 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17532997 | 0.83 | NTRK1 (0.51) | NTRK1MAP4K4MEN1KMT2A | |
| SCHEMBL623961 | 0.82 | MAP4K4 (0.57) | NTRK1MAP4K4CYP1A2KCNH2MINK1 | |
| SCHEMBL625203 | 0.80 | MAP4K4 (0.50) | NTRK1MAP4K4CYP1A2KCNH2MINK1 | |
| SCHEMBL17360450 | 0.78 | NTRK1 (0.73) | NTRK1 | |
| SCHEMBL17360475 | 0.78 | NTRK1 (0.73) | NTRK1 | |
| SCHEMBL6509007 | 0.78 | NPSR1 (0.57) | NPSR1CYP1A2KCNH2MEN1NPC1 | |
| SCHEMBL17360185 | 0.77 | NTRK1 (0.80) | NTRK1 | |
| SCHEMBL17360302 | 0.77 | NTRK1 (0.73) | NTRK1 | |
| SCHEMBL17360092 | 0.77 | NTRK1 (0.71) | NTRK1 | |
| SCHEMBL870523 | 0.75 | BTK (0.51) | NTRK1MAP4K4CYP1A2KCNH2MINK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3800183-A1 | UREA DERIVATIVES AS TRK-INHIBITING COMPOUNDS | ONO Pharmaceutical Co., Ltd. (JP) | 2021-04-07 | — | — | EP | disclosed |
| EP-3800183-A1 | UREA DERIVATIVES AS TRK-INHIBITING COMPOUNDS | ONO Pharmaceutical Co., Ltd. (JP) | 2021-04-07 | — | — | EP | disclosed |
| EP-3459935-B1 | UREA DERIVATIVE AS TRK-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2020-12-23 | — | — | EP | disclosed |
| US-10765676-B2 | Trk-inhibiting compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-09-08 | — | — | US | disclosed |
| US-10765676-B2 | Trk-inhibiting compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-09-08 | — | — | US | disclosed |
| US-20190231777-A1 | Trk-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-08-01 | — | — | US | disclosed |
| US-20190231777-A1 | Trk-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-08-01 | — | — | US | disclosed |
| US-10300060-B2 | Trk-inhibiting compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-05-28 | — | — | US | disclosed |
| US-10300060-B2 | Trk-inhibiting compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-05-28 | — | — | US | disclosed |
| EP-3459935-A1 | TRK-INHIBITING COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2019-03-27 | — | — | EP | disclosed |
| US-9463192-B2 | Trk-inhibiting compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-10-11 | — | — | US | disclosed |
| US-9463192-B2 | Trk-inhibiting compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-10-11 | — | — | US | disclosed |
| US-20160280684-A1 | TRK-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-09-29 | — | — | US | disclosed |
| US-20160280684-A1 | TRK-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-09-29 | — | — | US | disclosed |
| US-20160280684-A1 | TRK-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-09-29 | — | — | US | disclosed |
| US-20160000783-A1 | Trk-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-01-07 | — | — | US | disclosed |
| US-20160000783-A1 | Trk-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-01-07 | — | — | US | disclosed |
| US-20160000783-A1 | Trk-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-01-07 | — | — | US | disclosed |
| EP-2960234-A1 | Trk-INHIBITING COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2015-12-30 | — | — | EP | disclosed |
| EP-2960234-A1 | Trk-INHIBITING COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2015-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10300060-B2 | Trk-inhibiting compound | LTK, ROR1, TRPV1 | NTRK1 33/4885MAP4K4 297/4885NPSR1 908/4885 |
| US-20160280684-A1 | TRK-INHIBITING COMPOUND | LTK, ROR1, TRPV1 | NTRK1 33/4885MAP4K4 297/4885NPSR1 908/4885 |
| US-20160000783-A1 | Trk-INHIBITING COMPOUND | LTK, ROR1, TRPV1 | NTRK1 33/4885MAP4K4 297/4885NPSR1 908/4885 |
| US-20190231777-A1 | Trk-INHIBITING COMPOUND | LTK, ROR1, TRPV1 | NTRK1 33/4885MAP4K4 297/4885NPSR1 908/4885 |
| US-10765676-B2 | Trk-inhibiting compound | LTK, ROR1, TRPV1 | NTRK1 33/4885MAP4K4 297/4885NPSR1 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.